Omega-3 Fatty Acid Augmentation of Citalopram Treatment for Patients With Major Depressive Disorder
Open accessThe DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The objective of this study was to explore the efficacy of combination therapy with citalopram plus omega-3 fatty acids versus citalopram plus placebo (olive oil) in the initial treatment of individuals with major depressive disorder (MDD). We hypothesized that combination therapy would lead not only to greater efficacy but also to a more rapid onset of therapeutic response. METHODS: Forty-two subjects participated in this 9-week randomized, masked, placebo-controlled study of combination therapy (two 1 g capsules containing a blend of 900 mg of eicosapentaenoic acid, 200 mg of and docosahexaenoic acid, and 100 mg of other omega-3 fatty acids twice daily plus citalopram) versus monotherapy (two 1 g capsules of olive oil per day plus citalopram) treatment of MDD. RESULTS: The combination therapy demonstrated significantly greater improvement in Hamilton Depression Rating scale scores over time (F = 7.32; df 1,177; P = 0.008) beginning at week 4 (t = -2.48; df 177; P = 0.014). CONCLUSIONS: Combination therapy was more effective than monotherapy in decreasing signs and symptoms of MDD during the 8 weeks of active treatment; however, combination therapy did not seem to enhance the speed of the initial antidepressant response. These findings suggest that there may be an advantage to combining omega-3 fatty acids with a selective serotonin uptake inhibitor in the initial treatment of individuals with MDD. A larger definitive study is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“However, a meta-analysis has shown that rTMS is inferior to ECT with regard to efficacy in TRD 188 .”
From Major depressive disorder (2016) · cites this paper as [188]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Merikangas, K. R., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.593 · Cited by 20,391 · cited 1×
“The estimated lifetime incidence of MDD in adults in the United States is more than 15%.(3) In 2000, the economic burden of depressive disorders in the United States was an estimated $83.”
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
(1976) · Medical Entomology and Zoology · Cited by 8,899
Development of a Rating Scale for Primary Depressive Illness
HAMILTON, M. (1967) · British Journal of Social and Clinical Psychology · doi:10.1111/j.2044-8260.1967.tb00530.x · Cited by 8,410
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K. R., Rush, A. J., Walters, E. E., & Wang, P. S. (2003) · JAMA · doi:10.1001/jama.289.23.3095 · Cited by 7,988 · cited 1×
“Exclusion criteria were: (1) diagnosis of psychotic disorders including psychotic depression and bipolar disorders; (2) current drug or alcohol abuse or dependence, or history of drug or alcohol abuse or dependence within the previous six months; (3) unstable medical or neurological conditions that were likely to inte…”
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879 · cited 1×
“Exclusion criteria were: (1) diagnosis of psychotic disorders including psychotic depression and bipolar disorders; (2) current drug or alcohol abuse or dependence, or history of drug or alcohol abuse or dependence within the previous six months; (3) unstable medical or neurological conditions that were likely to inte…”
The ESEMeD/MHEDEA 2000 Investigators, Alonso, J., Angermeyer, M. C., Bernert, S., Bruffaerts, R., Brugha, T. S., Bryson, H., de Girolamo, G., de Graaf, R., Demyttenaere, K., et al. (2004) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0047.2004.00327.x · Cited by 1,819 · cited 1×
“Major depressive disorder (MDD) is the most prevalent Axis I disorder and one of the leading causes of disability in the United States and worldwide.(1,2) The estimated lifetime incidence of MDD in adults in the United States is more than 15%.”
The Economic Burden of Depression in the United States: How Did It Change Between 1990 and 2000?
Greenberg, P. E., Kessler, R. C., Birnbaum, H. G., Leong, S. A., Lowe, S. W., Berglund, P. A., & Corey-Lisle, P. K. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n1211 · Cited by 1,280
Nemets, B., Stahl, Z., & Belmaker, R. H. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.3.477 · Cited by 627
Peet, M., & Horrobin, D. F. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.10.913 · Cited by 614
Research works printed but not linked: 1
- Beck AT. Depression Inventory. Center for Cognitive Therapy; Philadelphia: 1978. [Google Scholar]
Cited by
Otte, C., Gold, S. M., Penninx, B. W., Pariante, C. M., Etkin, A., Fava, M., Mohr, D. C., & Schatzberg, A. F. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.65 · Cited by 2,269
Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications
Felger, J. C., & Lotrich, F. E. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.04.060 · Cited by 1,180
“Omega-3 fatty acids have increased the antidepressant efficacy of fluoxetine (Jazayeri et al., 2010) and citalopram (Gertsik et al., 2012), and a meta-analysis reported direct antidepressant effects when combining all sources of omega-3 fatty acids (e.g. docosahexaenoic acid, fish oils) (Lin and…”
BackgroundInflamed moods: A review of the interactions between inflammation and mood disorders
Rosenblat, J. D., Cha, D. S., Mansur, R. B., & McIntyre, R. S. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2014.01.013 · Cited by 609
Dietary patterns and depression risk: a meta-analysis
Li, Y., Lv, M.-R., Wei, Y.-J., Sun, L., Zhang, J.-X., Zhang, H.-G., & Li, B. (2017) · Psychiatry Research · doi:10.1016/j.psychres.2017.04.020 · Cited by 599
“Besides, recent evidence also suggests that adding omega3 fatty acids to antidepressants may improve mood in major depression (Gertsik et al., 2012; Freeman et al., 2006).”
Grosso, G., Pajak, A., Marventano, S., Castellano, S., Galvano, F., Bucolo, C., Drago, F., & Caraci, F. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096905 · Cited by 449
“Compared with previous meta-analyses, the differences of findings may depend on the additional number of RCTs published since the publication of the last study [37,40,53,60,61,66,68,69,84,89,92,94–97,100–102], the increasing number of participants which vary the overall weight of previous studies, the requirement for…”
MethodResultAdjunctive Nutraceuticals for Depression: A Systematic Review and Meta-Analyses
Sarris, J., Murphy, J., Mischoulon, D., Papakostas, G. I., Fava, M., Berk, M., & Ng, C. H. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.15091228 · Cited by 436
Efficacy of omega-3 PUFAs in depression: A meta-analysis
Liao, Y., Xie, B., Zhang, H., He, Q., Guo, L., Subramanieapillai, M., Fan, B., Lu, C., & McIntyre, R. S. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0515-5 · Cited by 404
Diet, Stress and Mental Health
Bremner, J., Moazzami, K., Wittbrodt, M., Nye, J., Lima, B., Gillespie, C., Rapaport, M., Pearce, B., Shah, A., & Vaccarino, V. (2020) · Nutrients · doi:10.3390/nu12082428 · Cited by 377
Self-citationMarkers of Oxidative Stress and Neuroprogression in Depression Disorder
Vaváková, M., Ďuračková, Z., & Trebatická, J. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2015/898393 · Cited by 324
“Combined therapy of SSRI antidepressants with n-3 PUFA indicated to be more effective than antidepressants monotherapy [5, 103].”
BackgroundMocking, R. J. T., Harmsen, I., Assies, J., Koeter, M. W. J., Ruhé, H. G., & Schene, A. H. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.29 · Cited by 279
Qaseem, A., Barry, M. J., Kansagara, D., & for the Clinical Guidelines Committee of the American College of Physicians (2016) · Annals of Internal Medicine · doi:10.7326/m15-2570 · Cited by 279
“Low-quality evidence from 2 trials (51, 52) showed no difference in overall discontinuation rates for SGA monotherapy compared with combination therapy of SGAs plus -3 fatty acids.”
BackgroundRapaport, M. H., Nierenberg, A. A., Schettler, P. J., Kinkead, B., Cardoos, A., Walker, R., & Mischoulon, D. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.22 · Cited by 265
Self-citationBai, S., Guo, W., Feng, Y., Deng, H., Li, G., Nie, H., Guo, G., Yu, H., Ma, Y., Wang, J., et al. (2020) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2019-320912 · Cited by 235
Gadad, B. S., Jha, M. K., Czysz, A., Furman, J. L., Mayes, T. L., Emslie, M. P., & Trivedi, M. H. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.07.001 · Cited by 205
Guu, T.-W., Mischoulon, D., Sarris, J., Hibbeln, J., McNamara, R. K., Hamazaki, K., Freeman, M. P., Maes, M., Matsuoka, Y. J., Belmaker, R. H., et al. (2019) · Psychotherapy and Psychosomatics · doi:10.1159/000502652 · Cited by 191
Song, C., Shieh, C.-H., Wu, Y.-S., Kalueff, A., Gaikwad, S., & Su, K.-P. (2016) · Progress in Lipid Research · doi:10.1016/j.plipres.2015.12.003 · Cited by 187
Efficacy of omega-3 highly unsaturated fatty acids in the treatment of depression
Hallahan, B., Ryan, T., Hibbeln, J. R., Murray, I. T., Glynn, S., Ramsden, C. E., SanGiovanni, J. P., & Davis, J. M. (2016) · British Journal of Psychiatry · doi:10.1192/bjp.bp.114.160242 · Cited by 188
“Thirteen strata compared DHA-predominant formulations with placebo, 5,8,11,16,18,19,22,26,27,29,30,47 17 strata compared selectively enriched EPA formulations with placebo, 2,6,9,13–15,21–23,25,48 and 22 strata compared mixed-EPA formulations to placebo.”
Omega-3 fatty acids for depression in adults
Appleton, K. M., Sallis, H. M., Perry, R., Ness, A. R., & Churchill, R. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004692.pub4 · Cited by 180
Supplementation with Omega-3 Fatty Acids in Psychiatric Disorders: A Review of Literature Data
Bozzatello, P., Brignolo, E., De Grandi, E., & Bellino, S. (2016) · Journal of Clinical Medicine · doi:10.3390/jcm5080067 · Cited by 179
“Interesting results were obtained from one study that explored the association of omega-3 fatty acids and antidepressants in treating depressed patients [39].”
Le Port, A., Gueguen, A., Kesse-Guyot, E., Melchior, M., Lemogne, C., Nabi, H., Goldberg, M., Zins, M., & Czernichow, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051593 · Cited by 180
“Furthermore, there is evidence that adding omega-3 fatty acids to antidepressants may improve mood in major depression [28,29].”
Du, J., Zhu, M., Bao, H., Li, B., Dong, Y., Xiao, C., Zhang, G. Y., Henter, I., Rudorfer, M., & Vitiello, B. (2016) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2013.876960 · Cited by 162
Food for Mood: Relevance of Nutritional Omega-3 Fatty Acids for Depression and Anxiety
Larrieu, T., & Layé, S. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.01047 · Cited by 162
Mood disorders and complementary and alternative medicine: a literature review
Qureshi, N. A., & Al-Bedah (2013) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s43419 · Cited by 155
“Finally, a placebo-controlled trial of adding omega-3 fatty acids to citalopram in patients with depression found significant improvement in depression scores compared with a placebo plus citalopram group, although there was no improvement in the speed of the initial antidepressant response.(120) An increased risk of…”
Oxidative/nitrosative stress and antidepressants: Targets for novel antidepressants
Lee, S., Lee, S.-J., Han, C., Patkar, A. A., Masand, P. S., & Pae, C. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.09.008 · Cited by 163
Van Dael, P. (2021) · Nutrition Research and Practice · doi:10.4162/nrp.2021.15.2.137 · Cited by 138
“Several lines of evidence have suggested the efficacy of n-3 LCPUFA as a MDD risk reduction or dietary management strategy in epidemiological and case-controlled studies [98,99], randomized-controlled trials [100-110], and meta-analyses [111-120].”
BackgroundGartlehner, G., Gaynes, B. N., Amick, H. R., Asher, G. N., Morgan, L. C., Coker-Schwimmer, E., Forneris, C., Boland, E., Lux, L. J., Gaylord, S., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m15-1813 · Cited by 132
“The available studies were compromised by unclear randomization methods, high loss to follow-up, small sample sizes, and lack of intention-to-treat analyses (23, 25, 28) (Table 5 of the Supplement).”
Schefft, C., Kilarski, L. L., Bschor, T., & Köhler, S. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.07.004 · Cited by 138
Elevated immune-inflammatory signaling in mood disorders: a new therapeutic target?
McNamara, R. K., & Lotrich, F. E. (2012) · Expert Review of Neurotherapeutics · doi:10.1586/ern.12.98 · Cited by 108
Evidence for Inflammation-Associated Depression
Liu, C. S., Adibfar, A., Herrmann, N., Gallagher, D., & Lanctôt, K. L. (2016) · Current topics in behavioral neurosciences · doi:10.1007/7854_2016_2 · Cited by 123
Pilecky, M., Závorka, L., Arts, M. T., & Kainz, M. J. (2021) · Biological reviews/Biological reviews of the Cambridge Philosophical Society · doi:10.1111/brv.12747 · Cited by 121
“There are multiple reports of PUFA supplementation significantly augmenting the antidepressant effects of selective serotonin reuptake inhibitors (Jazayeri et al., 2008; Laino et al., 2010; Gertsik et al., 2012), probably due to increased signal efficiency and transduction via 5-HT receptors.”
BackgroundPharmacometabolomic mapping of early biochemical changes induced by sertraline and placebo
Kaddurah-Daouk, R., Bogdanov, M. B., Wikoff, W. R., Zhu, H., Boyle, S. H., Churchill, E., Wang, Z., Rush, A. J., Krishnan, R. R., Pickering, E., et al. (2013) · Translational Psychiatry · doi:10.1038/tp.2012.142 · Cited by 101
“tion of SSRI citalopram treatment produced a significantly greater reduction in HAM-D scores compared with citalopram treatment alone.(42) In a yeast model, sertraline has been”
ResultAre medical comorbid conditions of bipolar disorder due to immune dysfunction?
Rosenblat, J. D., & McIntyre, R. S. (2015) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12414 · Cited by 97
Ota, K. T., & Duman, R. S. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.05.022 · Cited by 94
Fernandes, M., Mutch, D., & Leri, F. (2017) · Nutrients · doi:10.3390/nu9030298 · Cited by 90
“However, the combination of fluoxetine and EPA was even more effective at reducing depressive symptoms (~81% decrease in baseline HDRS) than either of them alone (≥50%–56% decrease in baseline HDRS) [117].”
BackgroundImmune-based strategies for mood disorders: facts and challenges
Colpo, G. D., Leboyer, M., Dantzer, R., Trivedi, M. H., & Teixeira, A. L. (2018) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2018.1407242 · Cited by 89
Omega-3 fatty acids for depression in adults
Appleton, K. M., Voyias, P. D., Sallis, H. M., Dawson, S., Ness, A. R., Churchill, R., & Perry, R. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004692.pub5 · Cited by 84
McNamara, R. K., Strimpfel, J., Jandacek, R., Rider, T., Tso, P., Welge, J. A., Strawn, J. R., & DelBello, M. P. (2014) · PharmaNutrition · doi:10.1016/j.phanu.2014.02.002 · Cited by 81
“However, the present findings are consistent with previous placebocontrolled trials finding that adjunctive LCn-3 fatty acid supplementation augmented SSRI efficacy in adult MDD patients [38,39].”
ResultDas, U. N. (2013) · Nutrition · doi:10.1016/j.nut.2013.01.012 · Cited by 83
“Furthermore, PUFAs have the ability to modulate the expression, properties, and action of dopamine, serotonin, and ACh [79–82], especially during the perinatal period during which the growth and development of brain is at maximum and ACh, in turn, regulates release of PUFAs [83].”
BackgroundCulpepper, L., Muskin, P. R., & Stahl, S. M. (2015) · The American Journal of Medicine · doi:10.1016/j.amjmed.2015.07.001 · Cited by 77
“Studies have shown that adding omega-3 fatty acids to current antidepressant treatment was more effective than antidepressant monotherapy.(82,83) Omega-3 fatty acids generally are well tolerated, but the optimum dose is unknown.”
BackgroundWang, C.-J., Yang, T.-F., Wang, G., Zhao, Y., Yang, L., & Bi, B.-N. (2017) · Psychiatry Research · doi:10.1016/j.psychres.2017.11.052 · Cited by 77
Polyunsaturated Fatty Acids: What is Their Role in Treatment of Psychiatric Disorders?
Bozzatello, P., Rocca, P., Mantelli, E., & Bellino, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215257 · Cited by 73
“The add-on therapy to citalopram with EPA, DHA and other PUFAs was found significantly more efficacious in reducing depression than single therapies, but with no changes in rapidity of initial antidepressant response [77].”
BackgroundBeyond Monoamines-Novel Targets for Treatment-Resistant Depression: A Comprehensive Review
D. Rosenblat, J., S. McIntyre, R., S. Alves, G., N. Fountoulakis, K., & F. Carvalho, A. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666150630175044 · Cited by 71
“Omega-3 polyunsaturated fatty acids with >60% EPA content has shown the greatest promise with several trials and meta-analyses showing a significant antidepressant effect of O3PUFA as an adjunct to SSRI therapy in the treatment of MDD [9, 53-55].”
BackgroundMessamore, E., Almeida, D. M., Jandacek, R. J., & McNamara, R. K. (2017) · Progress in Lipid Research · doi:10.1016/j.plipres.2017.01.001 · Cited by 68
Gharekhani, A., Khatami, M., Dashti‐Khavidaki, S., Razeghi, E., Noorbala, A.-A., Nazari, S. S. H., & Mansournia, M. A. (2014) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-014-1666-1 · Cited by 72
“Although monotherapy with omega-3 fatty acids for major depressive disorder has been shown to be effective [30, 37], existent evidence encourages the use of omega-3 fatty acids as augmentation of standard anti-depressants [37, 38].”
Liu, C., Carvalho, A., & McIntyre, R. (2015) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527313666141130204031 · Cited by 61
ω-3 Fatty acids for major depressive disorder in adults: an abridged Cochrane review
Appleton, K. M., Sallis, H. M., Perry, R., Ness, A. R., & Churchill, R. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-010172 · Cited by 60
Polyunsaturated fatty acid associations with dopaminergic indices in major depressive disorder
Sublette, M. E., Galfalvy, H. C., Hibbeln, J. R., Keilp, J. G., Malone, K. M., Oquendo, M. A., & Mann, J. J. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713001399 · Cited by 57
“…findings in randomized placebo-controlled trials that antidepressant efficacy of omega-3 supplementation is equivalent to and also additive to that of the serotonergic reuptake inhibitor fluoxetine (Jazayeri et al., 2008); and similarly additive to the effects of citalopram (Gertsik et al., 2012).”
Messamore, E., & McNamara, R. K. (2016) · Lipids in Health and Disease · doi:10.1186/s12944-016-0196-5 · Cited by 72
“In these studies, adjunctive LCn-3 fatty acid treatment augmented the therapeutic efficacy of fluoxetine [168] or citalopram [169].”
BackgroundLuo, X., Feng, J., Yang, Z., Huang, Q., Lin, J., Yang, B., Su, K., & Pan, J. (2020) · BMC Psychiatry · doi:10.1186/s12888-020-02656-3 · Cited by 68
Simon, M. S., Arteaga-Henríquez, G., Algendy, A. F., Siepmann, T., & Illigens, B. M. W. (2023) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s385117 · Cited by 66
Mitochondrial dysfunction in psychiatric disorders
Ni, P., Ma, Y., & Chung, S. (2022) · Schizophrenia Research · doi:10.1016/j.schres.2022.08.027 · Cited by 69
Triglyceride and fatty acid composition of ruminants milk, human milk, and infant formulae
Wang, X., Zhu, H., Zhang, W., Zhang, Y., Zhao, P., Zhang, S., Pang, X., Vervoort, J. J. M., Lü, J., & Lv, J. (2021) · Journal of Food Composition and Analysis · doi:10.1016/j.jfca.2021.104327 · Cited by 53
Kalkman, H. O., Hersberger, M., Walitza, S., & Berger, G. E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094393 · Cited by 58
McNamara, R. K. (2016) · Journal of Nutrition & Intermediary Metabolism · doi:10.1016/j.jnim.2016.04.004 · Cited by 58
“Controlled and open-label trials have also observed greater reductions in depressive symptoms by combining LCn-3 fatty acids with SSRI medications (Gertsik et al., 2012; Jazayeri et al., 2008; McNamara et al., 2014a; Peet & Horrobin, 2002).”
BackgroundDu, Y., Dou, Y., Wang, M., Wang, Y., Yan, Y., Fan, H., Fan, N., Yang, X., & Ma, X. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1407529 · Cited by 66
Baek, D., & Park, Y. (2013) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2013.09.008 · Cited by 53
“Clinical benefits of n-3 PUFA supplements have also been reported in several [14,15], but not all [16,17] randomized controlled trials.”
BackgroundRole of long-chain omega-3 fatty acids in psychiatric practice
McNamara, R. K., & Strawn, J. R. (2013) · PharmaNutrition · doi:10.1016/j.phanu.2012.10.004 · Cited by 48
BDNF as a Mediator of Antidepressant Response: Recent Advances and Lifestyle Interactions
Cubillos, S., Engmann, O., & Brancato, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214445 · Cited by 47
“4 g/d Citalopram 20–40 mg/d HDRS: Fatty acids < placebo [88] EPA 0.”
BackgroundOmega-3 polyunsaturated fatty acids for major depressive disorder
Su, K.-P., Wang, S.-M., & Pae, C.-U. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.836487 · Cited by 47
“Despite well-controlled clinical trials and systematic meta-analyses which have demonstrated the potential utility of omega-3 PUFA in the treatment of MDD [20,26-28,31,91-97,116], it is not clearly shown whether the efficacy of omega-3 PUFAs’ antidepressant effects should be potentially different for specific subtypes…”
MethodResultOmega-3 Fatty Acids for Depression in Multiple Sclerosis: A Randomized Pilot Study
Shinto, L., Marracci, G., Mohr, D. C., Bumgarner, L., Murchison, C., Senders, A., & Bourdette, D. (2016) · PLOS ONE · doi:10.1371/journal.pone.0147195 · Cited by 46
Gartlehner, G., Dobrescu, A., Chapman, A., Toromanova, A., Emprechtinger, R., Persad, E., Affengruber, L., Pieh, C., Klerings, I., & Wagner, G. (2023) · Annals of Internal Medicine · doi:10.7326/m22-1845 · Cited by 43
“Comparison of response to treatment of nonpharmacologic interventions with SGAs.”
BackgroundInfluentialMocking, R. J. T., Verburg, H. F., Westerink, A. M., Assies, J., Vaz, F. M., Koeter, M. W. J., Ruhé, H. G., & Schene, A. H. (2015) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2015.04.027 · Cited by 50
Hixson, S. M., Parrish, C. C., & Anderson, D. M. (2013) · Fish Physiology and Biochemistry · doi:10.1007/s10695-013-9798-2 · Cited by 50
Traditional and Alternative Treatments for Depression: Implications for Migraine Management
Peck, K. R., Smitherman, T. A., & Baskin, S. M. (2015) · Headache The Journal of Head and Face Pain · doi:10.1111/head.12521 · Cited by 46
“Limited research suggests that folic acid or methylfolate may be effective and well tolerated in reducing symptoms of depression among individuals with low folate levels or as an augmentation strategy for those who are treatment resistant.66,67 S-adenosyl methionine (SAMe) is a methyl donor to many neurotransmitters a…”
BackgroundHang, X., Zhang, Y., Li, J., Li, Z., Zhang, Y., Ye, X., Tang, Q., & Sun, W. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.691200 · Cited by 47
“Included studies Diagnostic criteria Sample size Experimental group Control group Followup time (weeks) Sponsor typeMean age (Years) Female Interventions Mean age (Years) Female Interventions NSAIDs Abbasi et al. (2012) DSM-IV-TR 40 35.1 ± 8.0 7 Sertraline 200 mg/d + celecoxib 400 mg/d 34.2 ± 6.9 6 Sertraline 200 mg/d…”
BackgroundInfluentialCzysz, A. H., & Rasenick, M. M. (2013) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527311312040005 · Cited by 42
“Further, recent data by Rapaport and colleagues demonstrate a clear advantage to n-3 PUFA supplementation of SSRI therapy [61].”
BackgroundNutritional strategies for dealing with depression
Manosso, L. M., Moretti, M., & Rodrigues, A. L. S. (2013) · Food & Function · doi:10.1039/c3fo60246j · Cited by 38
Effects of Omega 3 Fatty Acids on Main Dimensions of Psychopathology
Bozzatello, P., Rosa, M. L. D., Rocca, P., & Bellino, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176042 · Cited by 35
“…patients) Placebo 66 patients with mild-to moderate depression aged > 66 years 24 weeks low-dose n-3PUFAs have some efficacy in mild to moderate depression Gertsik et al., 2012 [106] EPA 0.9 g/day + DHA 0.2 g/day + other n-3 PUFAs (0.1 g/day) added to citalopram Placebo added to citalopram 42…”
InfluentialOmega-3 Fatty Acids Supplementation in the Treatment of Depression: An Observational Study
Mehdi, S., Kishor, M. R., Shariff, A., Kinattingal, N., Wani, S. U. D., Alshehri, S., Imam, M. T., Shakeel, F., & Krishna, K. L. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13020224 · Cited by 43
Asher, G. N., Gartlehner, G., Gaynes, B. N., Amick, H. R., Forneris, C. A., Morgan, L. C., Coker‐Schwimmer, E., Boland, E., Lux, L. J., Gaylord, S. A., et al. (2017) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.2016.0261 · Cited by 39
“…those treated with either SSRI or omega-3 fatty acid monotherapy (combination treatment vs. citalopram: 44% vs. 18% for remission, p - value not reported 28 ; combination treatment vs. fluoxetine: 81% vs. 50% for treatment response, p = 0.005, EPA mono-therapy vs. fluoxetine: 56% vs. 50%, p = 0.43).”
InfluentialZhao, W., Hylton, N. K., Wang, J. P., Chindavong, P. S., Alural, B., Kurtser, I., Subramanian, A., Mazitschek, R., Perlis, R. H., & Haggarty, S. J. (2019) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2019.06.006 · Cited by 41
“[35] found citalopram plus EPA/DHA/other PUFA (poly-unsaturated fatty acids) co-treatment significantly decreased the symptoms of MDD in comparison to monotherapy.”
ResultSublette, M. E., Daray, F. M., Ganança, L., & Shaikh, S. R. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02322-6 · Cited by 37
“…directly comparing n-3 LC-PUFA treatment and selective serotonin reuptake inhibitors (SSRIs), one [54] found equivalent effect sizes for fl uoxetine and EPA monotherapy, and both studies [54, 55] found greater ef fi cacy when the SSRI was combined with an EPA-rich supplement or EPA monotherapy.”
Fish oil and depression: The skinny on fats
Burhani, M. D., & Rasenick, M. M. (2017) · Journal of Integrative Neuroscience · doi:10.3233/jin-170072 · Cited by 38
Ma, S., Xie, X., Deng, Z., Wang, W., Xiang, D., Yao, L., Kang, L., Xu, S., Wang, H., Wang, G., et al. (2023) · Biological Psychiatry · doi:10.1016/j.biopsych.2023.12.015 · Cited by 36
Cutler, J. B. R., Pane, O., Panesar, S., Updike, W. H., & Moore, T. R. (2023) · Journal of Midwifery & Women s Health · doi:10.1111/jmwh.13527 · Cited by 32
The role of n-3 polyunsaturated fatty acids (n-3PUFAs) in affective disorders
Ciappolino, V., Delvecchio, G., Agostoni, C. V., Mazzocchi, A., Altamura, A. C., & Brambilla, P. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.12.034 · Cited by 31
Trebatická, J., Hradečná, Z., Böhmer, F., Vaváková, M., Waczulíková, I., Garaiová, I., Luha, J., Škodáček, I., Šuba, J., & Ďuračková, Z. (2017) · Child and Adolescent Psychiatry and Mental Health · doi:10.1186/s13034-017-0167-2 · Cited by 30
Neuroenhancement of Exposure Therapy in Anxiety Disorders
Hofmann, S. G., Mundy, E. A., & Curtiss, J. E. (2015) · AIMS neuroscience · doi:10.3934/neuroscience.2015.3.123 · Cited by 31
“Despite the dearth of evidence supporting the efficacy of omega-3 fatty acid supplements, several studies have investigated them as an adjunct to pharmacological treatment for depression, bipolar disorder, and attention deficit hyperactivity disorder, revealing modest findings [88,89,91,92].”
Giakoumatos, C. I., & Osser, D. (2019) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000197 · Cited by 27
Cognitive enhancers for the treatment of anxiety disorders
Hofmann, S. G., Fang, A., & Gutner, C. A. (2014) · Restorative Neurology and Neuroscience · doi:10.3233/rnn-139002 · Cited by 33
“…of omega-3 supplements for anxiety disorders has been even investigated the benefits of omega-3 supplements as adjunct to pharmacologic treatment for depression, bipolar disorder, and attention deficit hyperactivity disorder 2011; Bloch & Qawasmi, 2011; Gertsik et al., 2012; Lesperanceetal.,2011).”
Li, S., Li, R., Hu, X., Zhang, Y., Wang, D., Gao, Y., Wang, J., Wang, Q., Song, C., Huang, S., et al. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.10.151 · Cited by 28
Ganança, L., Galfalvy, H., Oquendo, M. A., Hezghia, A., Cooper, T. B., Mann, J. J., & Sublette, M. E. (2017) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2017.03.004 · Cited by 27
“In clinical trials examining augmentation strategies greater improvements in depression were reported when adding omega-3 PUFAs to fluoxetine [40] and citalopram [41] compared to the SSRIs alone.”
The Role of Docosahexaenoic Acid (DHA) on Cognitive Functions in Psychiatric Disorders
Ciappolino, V., Mazzocchi, A., Botturi, A., Turolo, S., Delvecchio, G., Agostoni, C. V., & Brambilla, P. (2019) · Nutrients · doi:10.3390/nu11040769 · Cited by 26
Able, J. A., Liu, Y., Jandacek, R., Rider, T., Tso, P., & McNamara, R. K. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.11.008 · Cited by 24
“Emerging evidence further suggests that adjunctive supplementation with LCn-3 fatty acids significantly augment the antidepressant effects of selective serotonin reuptake inhibitor (SSRI) medications (Jazayeri et al., 2008; Gertsik et al., 2012; Peet and Horrobin, 2002).”
BackgroundZemdegs, J., Rainer, Q., Grossmann, C. P., Rousseau-Ralliard, D., Grynberg, A., Ribeiro, E., & Guiard, B. P. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00974 · Cited by 23
Converged avenues: depression and Alzheimer’s disease– shared pathophysiology and novel therapeutics
Bajaj, S., & Mahesh, R. (2024) · Molecular Biology Reports · doi:10.1007/s11033-023-09170-1 · Cited by 28
Cussotto, S., Delgado, I., Oriolo, G., Kemper, J., Begarie, D., Dexpert, S., Sauvant, J., Leboyer, M., Aouizerate, B., Martín‐Santos, R., et al. (2022) · Depression and Anxiety · doi:10.1002/da.23257 · Cited by 27
“Results from these clinical dietary studies reported a beneficial contribution of supplementations with EPA, DHA or a combination of both on the therapeutic effects of antidepressant drugs (Gertsik et al., 2012; Jazayeri et al., 2008).”
BackgroundCannabinoids in Health and Disease
Meccariello, R., & Chianese, R. (2016) · InTech eBooks · doi:10.5772/61595 · Cited by 22
Sarris, J. J., Stough, C. K. K., Bousman, C., Murphy, J., Savage, K. M., Smith, D. J., Menon, R., Chamoli, S., Oliver, G., Berk, M., et al. (2015) · Advances in Integrative Medicine · doi:10.1016/j.aimed.2015.02.001 · Cited by 19
“[23] used 900 mg of EPA and 200 mg of DHA (or placebo) adjunctively with citalopram in the treatment of MDD.”
MethodAssociations between major dietary patterns and anxiety in middle-aged adults in eastern China
Xu, F., Chong, B.-Q., Cai, T., Zhang, J., & Lv, J. (2020) · Public Health Nutrition · doi:10.1017/s1368980020000221 · Cited by 20
“Evidence suggests that the addition of n-3 fatty acids to antidepressants might improve mood in major depression(41).”
BackgroundDogaru, I.-A., Puiu, M. G., Manea, M., & Dionisie, V. (2022) · Brain Sciences · doi:10.3390/brainsci12101403 · Cited by 23
Fish oil as a management component for mood disorders – an evolving signal
Hegarty, B. D., & Parker, G. B. (2012) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e32835ab4a7 · Cited by 20
Wu, S., Chen, W.-J., Chang, J. P., Guu, T., Hsin, M.-C., Huang, C., Mischoulon, D., Capuron, L., & Su, K. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13061003 · Cited by 21
“Furthermore, supplementation with these fatty acids in the form of fish oil is comparable to commonly used antidepressant drugs [94,95].”
ResultDietary Omega-6/Omega-3 and Endocannabinoids: Implications for Brain Health and Diseases
Bosch‐Bouju, C., & Layé, S. (2016) · InTech eBooks · doi:10.5772/62498 · Cited by 28
“Some trials showed no convincing effect while others demonstrated that ω-3 supplementation for 8-12 weeks have significant positive effects, notably because it improves the efficiency of antide‐ pressants and thus increases the proportion of remission [134].”
BackgroundEffects of n-3 PUFA enriched and n-3 PUFA deficient diets in naïve and Aβ-treated female rats
Bové, M., Mhillaj, E., Tucci, P., Giardino, I., Schiavone, S., Morgese, M. G., & Trabace, L. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.07.017 · Cited by 20
Yang, R., Wang, L., Jin, K., Cao, S., Wu, C., Guo, J., Chen, J., Tang, H., & Tang, M. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.876152 · Cited by 26
“Among them, only 50−70% of the patients respond to a single antidepressant medication (3, 4).”
BackgroundErythrocyte Membrane Fatty Acid Composition as a Potential Biomarker for Depression
Liu, T., Wang, L., Guo, J., Zhao, T., Tang, H., Dong, F., Wang, C., Chen, J., & Tang, M. (2023) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyad021 · Cited by 18
“Furthermore, numerous clinical trials have demonstrated efficacy of certain n-3 PUFAs as a depression adjuvant therapy (Jazayeri et al., 2008; Gertsik et al., 2012; Jahangard et al., 2018), and changes in docosahexaenoic acid (DHA) levels after fish oil supplementation were associated with the…”
BackgroundRole of Inflammation in Psychiatric Disorders
Jeon, S. W., Yoon, H.-K., & Kim, Y. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9721-0_24 · Cited by 21
Masoumi, S. Z., Kazemi, F., Tavakolian, S., Rahimi, A., Oshvandi, K., Soltanian, A. R., & Shobeiri, F. (2016) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2016/19487.8597 · Cited by 21
The effect of chronotherapy on depressive symptoms: Evidence-based practice
Khalifeh, A. H. (2017) · Saudi Medical Journal · doi:10.15537/smj.2017.5.18062 · Cited by 23
Metadata
- Authors
- Gertsik, L., Poland, R. E., Bresee, C., & Rapaport, M. H.
- Affiliations
- Cedars-Sinai Medical Center (US)
- Meharry Medical College (US)
- Corresponding author
- Gertsik, Lev
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2012-02
- Volume
- 32
- Issue
- 1
- Pages
- 61-64
- ISSN
- 0271-0749 (ISSN-L)
- PMC
- PMC3375825
- OpenAlex
- W2069184109
- Semantic Scholar
- 1baeee66cc47765e9086c7363078b259186a30f9
- Cited by
- 162
- References
- 37
- Citations by year
- 2025: 5 · 2024: 6 · 2023: 14 · 2022: 6 · 2021: 6 · 2020: 9 · 2019: 13 · 2018: 9 · 2017: 17 · 2016: 21 · 2015: 22 · 2014: 10 · 2013: 19 · 2012: 5
- FWCI
- 10.05
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (UL1TR000124)
- National Center for Research Resources (U54RR026140, M01RR000425)
- National Center for Advancing Translational Sciences
- National Institute on Minority Health and Health Disparities (U54MD007593)
- National Center for Complementary and Integrative Health (R21AT001077)
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- omega-3 fatty acids, citalopram, major depressive disorder, combination therapy, eicosapentaenoic acid, docosahexaenoic acid, selective serotonin reuptake inhibitors, antidepressant response, olive oil placebo
- MeSH terms
- Adult, Depressive Disorder, Major, Major Depressive Disorder, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Citalopram, Fatty Acids, Omega-3, Treatment Outcome, Antidepressive Agents, Second-Generation, Dietary Supplements
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.